2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation
1993
How 2'-deoxy-5-azacytidine Helps Cisplatin Bind to DNA
publication
Evidence: moderate
Author Information
Author(s): J.A. Ellerhorst, P. Frost, J.L. Abbruzzese, R.A. Newman, Y. Chernajovsky
Primary Institution: The University of Texas, M.D. Anderson Cancer
Hypothesis
The study investigates the molecular mechanisms underlying the synergy between 2'-deoxy-5-azacytidine (DAC) and cisplatin (cDDP) in enhancing cDDP binding to DNA.
Conclusion
The study concludes that DAC increases cDDP binding to DNA through mechanisms independent of DNA hypomethylation.
Supporting Evidence
- DAC enhances cDDP binding to DNA without acting as a hypomethylating agent.
- Both in vitro and in vivo studies confirmed that methylated DNA binds more cDDP than unmethylated DNA.
- The study utilized flameless atomic absorption spectrophotometry to measure cDDP binding.
Takeaway
This study shows that a drug called DAC can help another drug, cisplatin, stick better to DNA, which might make it work better against cancer.
Methodology
The study used in vitro experiments with plasmid DNA and CMT3 cells to measure cDDP binding and the effects of DAC.
Want to read the original?
Access the complete publication on the publisher's website